Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Brigitte Brieschke, Garrett L. Robinson, Sangeetha Rajagopalan, Hilario J. Ramos, Jensing Liu, Jack P. Higgins and Erin K. Willert | ||||||||||||
Title | Targeted Engineered Toxin Bodies provide a novel mechanism of action against HER2 positive cancers | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/78/13_Supplement/5769.short | ||||||||||||
Abstract Text | Cancer Res 2018;78(13 Suppl):Abstract nr 5769 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MT-5111 | MT5111|MT 5111 | HER2 (ERBB2) Antibody 72 | MT-5111 is an Erbb2 (Her2) antibody in conjugation with a ribosome-targeting toxin, which may demonstrate cytotoxicity against Erbb2 (Her2)-positive tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 5769). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|